Opexa ODT
Generic Name
Olanzapine Orally Disintegrating Tablet
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| opexa odt 10 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Opexa ODT (Olanzapine) is an atypical antipsychotic medication used to treat schizophrenia and bipolar I disorder. It is an orally disintegrating tablet that dissolves rapidly in the mouth.
Uses & Indications
Dosage
Adults
Schizophrenia: Initial dose 5-10 mg once daily, target dose 10 mg once daily. Bipolar I Disorder (manic/mixed episodes): Initial dose 10-15 mg once daily. Maintenance: 10 mg once daily.
Elderly
Consider a lower starting dose (e.g., 5 mg/day) and slower titration for elderly patients, especially those with increased susceptibility to side effects.
Renal_impairment
No routine dosage adjustment is required for renal impairment, but caution is advised in severe cases. Consider lower initial doses.
How to Take
Take Opexa ODT once daily, with or without food. Place the tablet in the mouth on the tongue; it will rapidly disintegrate. Swallow with saliva. Do not chew or cut the tablet. Do not remove from blister until just before use.
Mechanism of Action
Olanzapine's antipsychotic activity is believed to be mediated through a combination of antagonism at D2 dopamine and 5-HT2A serotonin receptors. It also has affinity for muscarinic, alpha-1 adrenergic, and histamine H1 receptors.
Pharmacokinetics
Onset
Antipsychotic effects may take several days to weeks to become fully apparent. Initial sedation can occur within hours.
Excretion
Approximately 57% of the dose is excreted in urine and 30% in feces, mainly as metabolites.
Half life
Approximately 21-54 hours (mean 33 hours) in healthy individuals.
Absorption
Well-absorbed after oral administration, peak plasma concentrations typically reached in 5-8 hours. Bioavailability is not affected by food.
Metabolism
Extensively metabolized in the liver, primarily via direct glucuronidation and cytochrome P450 (CYP1A2 and CYP2D6) mediated oxidation. CYP1A2 is the major metabolic enzyme.
Side Effects
Contraindications
- •Known hypersensitivity to olanzapine or any component of the formulation.
- •Patients with known angle-closure glaucoma (or narrow angle at risk) due to its anticholinergic effect.
Drug Interactions
Anticholinergic Drugs
Increased risk of anticholinergic side effects (e.g., dry mouth, constipation, urinary retention).
CNS Depressants (e.g., alcohol, benzodiazepines)
Increased risk of sedation and respiratory depression.
CYP1A2 Inhibitors (e.g., fluvoxamine, ciprofloxacin)
May increase olanzapine levels, requiring dose reduction.
CYP1A2 Inducers (e.g., carbamazepine, rifampicin, smoking)
May decrease olanzapine levels, requiring dose increase.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include somnolence, tachycardia, agitation, dysarthria, various extrapyramidal symptoms, and decreased consciousness. Management is supportive, including maintaining an open airway, oxygenation, ventilation, and monitoring cardiovascular status. Activated charcoal may be useful.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Excreted into breast milk; breastfeeding is not recommended during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date
Availability
Available in pharmacies nationwide
Approval Status
Approved by major regulatory bodies (e.g., FDA, DGDA)
Patent Status
Generic available; original patent expired
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in